Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Rivian Automotive Stock Will Have a Long Road Back to Its $180 Highs

By Chris Lau, InvestorPlace Contributor

RIVN stock peaked at $179.47 before falling the next day, as momentum faded post-IPO and bad news circled the stock.

Buy and Hold Meta Platforms as Metaverse Growth Strategy Unfolds

By Chris Lau, InvestorPlace Contributor

Meta Platforms is about to re-accelerate growth on AR/VR in the future, while it manages advertising revenue growth now.

Jumia Stock May Be Worth a Look for Some Investors

By Chris Lau, InvestorPlace Contributor

Speculators dumped JMIA stock throughout this year when they realized it is not the next Amazon or MercadoLibre.

7 Drug Stocks to Buy Now While They’re Still on Sale

By Chris Lau, InvestorPlace Contributor

Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead.

Why Skillz Is a Disappointment as Bears Bet Against it

By Chris Lau, InvestorPlace Contributor

SKLZ stock has to prove itself to shareholders, who are growing impatient waiting for its acquisitions to add meaningfully to profits.

Load More